Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - Associated facial angiofibroma

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 10, 2012, Pages 1315-1318

  Salido, R ^a   Garnacho Saucedo, G ^a   Cuevas Asencio, I ^a   Ruano, J ^a   Galan Gutierrez M ^a   Velez A ^a   Moreno Gimenez J C ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMANGIOFIBROMA; HUMAN; LIMIT OF DETECTION; MALE; OINTMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TUBEROUS SCLEROSIS; TUBEROUS SCLEROSIS ASSOCIATED FACIAL ANGIOFIBROMA;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ANGIOFIBROMA; CHILD; FACE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SIROLIMUS; TUBEROUS SCLEROSIS; YOUNG ADULT;

EID: 84866236400     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04212.x     Document Type: Article

References (11)

1. Sampson JR,. Therapeutic targeting of mTOR in tuberous sclerosis. Biochem Soc Trans 2009; 37: 259-264.
2. Schepis C, Siragusa M,. Cryosurgery: an easy and cheap therapy for facial angiofibromas in tuberous sclerosis. Eur J Dermatol 2010; 20: 506-507.
3. Weinberger CH, Endrizzi B, Hook KP, et al. Treatment of angiofibromas of tuberous sclerosis with 5-aminolevulinic acid blue light photodynamic therapy followed by immediate pulsed dye laser. Dermatol Surg 2009; 35: 1849-1851.
4. Weiss ET, Geronemus RG,. New technique using combined pulsed dye laser and fractional resurfacing for treating facial angiofibromas in tuberous sclerosis. Lasers Surg Med 2010; 42: 357-360.
5. Rauktys A, Lee N, Lee L, Dabora SL,. Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol 2008; 8: 1.
6. Ormerod AD, Shah SA, Copeland P, Omar G, Winfield A,. Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Dermatol 2005; 152: 758-764.
7. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-151.
8. Hofbauer GF, Marcollo-Pini A, Corsenca A, et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol 2008; 159: 473-475.
9. Tarasewicz A, Debska-Slizień A, Konopa J, et al. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. Transplant Proc 2009; 41: 3677-3682.
10. Haemel AK, O'Brian AL, Teng JM,. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol 2010; 146: 715-718.
11. Kaufman McNamara E, Curtis AR, Fleischer AB Jr,. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin. J Dermatolog Treat 2010; doi: 10.3109/09546634.2010.489598 [Epub ahead of print].